Humacyte HUMA
NASDAQ HUMA
$0.40 -0.01 (-2.16%)
As of: Oct 22, 2026 · 9:55 AM EDT

Humacyte (HUMA) Gross Margin (2025 - 2026)

Updated

Humacyte's Gross Margin came in at -203.20% for Q2 2026, down 232.44 percentage points from 29.24% a year earlier but up 108.52 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Gross Margin (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Humacyte reported Gross Margin of -494.58%, down 550.57 percentage points year-over-year; for FY2025, it was -376.05%.

  • The five-year range for quarterly Gross Margin is -1844.75% (Q4 2025) to 71.57% (Q1 2025).
  • Business Quant data shows HUMA's Gross Margin at -311.72% (Q1 2026), -1844.75% (Q4 2025) and 65.47% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,160.65 Bn 1,129.23 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 633.19 Bn 551.72 Bn 17.26 Bn 68.19%
3 AbbVie 501.90 Bn 475.01 Bn 12.70 Bn 74.74%
4 Merck 377.07 Bn 331.45 Bn 12.21 Bn 73.54%
5 Novartis Ag 302.35 Bn 266.34 Bn 11.24 Bn 78.02%
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 83.60%
7 Amgen 240.68 Bn 196.07 Bn 7.24 Bn 72.04%
8 Gilead Sciences 193.20 Bn 167.40 Bn 6.22 Bn 79.76%
9 Pfizer 172.14 Bn 118.78 Bn 10.94 Bn 72.78%
10 Humacyte 93.67 Mn -104.77 Mn -825,000.00 -203.20%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -203.20%
Mar 31, 2026 -311.72%
Dec 31, 2025 -1,844.75%
Sep 30, 2025 65.47%
Jun 30, 2025 29.24%
Mar 31, 2025 71.57%
API Access

Humacyte Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY